Company Overview
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Why Investors Should Care
Revenue has grown at a 37.8% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.19.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $1.94B (-39.9% YoY); net profit $-2.82B.
- Trailing 12 Months Year-on-year growth — revenue +2.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 37.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 37.82% |
| 1 Year: | 2.10% |
Stock Price Performance
| 1 Year: | +441.28% |
| 6 Months: | +177.13% |
| 3 Months: | +206.81% |
| 1 Month: | +170.24% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)63.19 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 37.8% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MRNA Moderna, Inc. SPXR3KPHARMA | 145.55 | -18.24 | $58.11B | 0.00% | -29.70% | -39.00% | 37.82% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 16.02M | 13.08M | 17.05M | - | - | - | - | - | - | - | - | - | 3.36B | 1.86B | 344.00M | 1.83B | 167.00M | 241.00M | 1.86B | 108.00M | 142.00M | 1.02B | 389.00M | 145.00M |
| Operating Income | -65.46M | -94.19M | -67.87M | -41.83M | -77.40M | -97.02M | -85.82M | -153.03M | -141.64M | -143.71M | -130.76M | -130.56M | -131.00M | -122.00M | -235.00M | 1.27B | 3.06B | 3.56B | 4.23B | 2.45B | 1.17B | -366.00M | -1.87B | -2.01B | -1.27B | -1.36B | -70.00M | -1.05B | -907.00M | -260.00M | -1.39B | -815.00M |
| Net Income | - | - | - | - | -72.38M | -90.60M | -80.33M | - | -132.58M | -134.94M | -123.22M | - | -124.00M | -117.00M | -233.00M | 1.22B | 2.78B | 3.33B | 3.66B | 2.20B | 1.04B | 79.00M | -1.38B | -3.63B | -1.18B | -1.28B | 13.00M | -971.00M | -825.00M | -200.00M | -1.34B | -782.00M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -0.35 | -0.31 | -0.59 | 2.84 | 6.46 | 7.70 | 8.58 | 5.24 | 2.53 | 0.19 | -3.62 | -9.53 | -3.07 | -3.33 | 0.03 | -2.52 | -2.13 | -0.51 | -3.40 | -1.97 |
| R&D Expense | - | - | - | - | 90.12M | 104.48M | 109.05M | - | 130.41M | 128.31M | 119.64M | - | 115.00M | 152.00M | 344.00M | 401.00M | 421.00M | 521.00M | 554.00M | 710.00M | 820.00M | 1.13B | 1.15B | 1.16B | 1.06B | 1.22B | 1.14B | 856.00M | 700.00M | 801.00M | 649.00M | 651.00M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 108.40M | 205.82M | 135.07M | 60.21M | 803.00M | 18.47B | 19.26B | 6.85B | 3.24B | 1.94B |
| Operating Income | -223.77M | -269.36M | -413.27M | -546.00M | -763.00M | 13.30B | 9.42B | -4.24B | -3.94B | -3.07B |
| Net Income | -216.21M | -255.92M | -384.73M | -514.00M | -747.00M | 12.20B | 8.36B | -4.71B | -3.56B | -2.82B |
| Diluted EPS | - | - | - | -1.55 | -1.96 | 28.29 | 20.12 | -12.33 | -9.28 | -7.26 |
| R&D Expense | 274.72M | 410.46M | 454.08M | 496.00M | 1.37B | 1.99B | 3.29B | 4.84B | 4.54B | 3.13B |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Jan 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 1.08B | 1.96B | 2.02B | 1.59B | 7.34B | 24.67B | 25.86B | 18.43B | 14.14B | 12.34B |
| Total Equity | -149.76M | -334.81M | -551.37M | 1.53B | - | 1.18B | 2.56B | 14.14B | 19.12B | 13.85B | 10.90B | 8.65B |
| Cash & Equivalents | 159.04M | 50.08M | 134.86M | 658.36M | - | 236.00M | 2.62B | 6.85B | 3.21B | 2.91B | 1.93B | 2.60B |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | 0 | 590.00M |
| Total Liabilities | - | - | 459.19M | 431.91M | - | 414.61M | 4.78B | 10.52B | 6.74B | 4.57B | 3.24B | 3.69B |
| Current Liabilities | - | - | 191.46M | 222.80M | - | 143.12M | 4.39B | 9.13B | 4.92B | 3.02B | 2.21B | 1.99B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 66.73M | -331.48M | -330.87M | -459.00M | 2.03B | 13.62B | 4.98B | -3.12B | -3.00B | -1.87B |
| Investing Cash Flow | -648.61M | 417.36M | -373.09M | -15.00M | -1.67B | -8.52B | -5.18B | 4.21B | 1.95B | 1.95B |
| Financing Cash Flow | 472.91M | 168.00K | 1.23B | 52.00M | 2.03B | -873.00M | -3.45B | -1.38B | 56.00M | 593.00M |
| Capital Expenditure | -33.14M | -58.40M | -105.77M | -32.00M | -68.00M | -284.00M | -400.00M | -707.00M | -1.05B | -192.00M |
| Free Cash Flow | 33.59M | -389.88M | -436.63M | -491.00M | 1.96B | 13.34B | 4.58B | -3.83B | -4.05B | -2.06B |
| Share Buybacks | - | - | - | 0 | 0 | 857.00M | 3.33B | 1.15B | 0 | 2.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -206.4% | -130.9% | -306.0% | -906.8% | -95.0% | 72.0% | 48.9% | -61.9% | -121.9% | -158.1% |
| Net Margin % | -199.5% | -124.3% | -284.8% | -853.7% | -93.0% | 66.1% | 43.4% | -68.8% | -110.0% | -145.2% |
| ROE % | 64.6% | 46.4% | -25.1% | -43.7% | -29.2% | 86.3% | 43.7% | -34.0% | -32.7% | -32.6% |
| ROCE % | - | -30.2% | -23.8% | -37.8% | -25.9% | 85.6% | 45.0% | -27.5% | -33.1% | -29.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 12.99% | 51.86M | $7.16B |
| 2 | Blackrock Inc. | 7.66% | 30.60M | $4.22B |
| 3 | Vanguard Capital Management LLC | 5.81% | 23.21M | $3.20B |
| 4 | Capital World Investors | 5.58% | 22.28M | $3.07B |
| 5 | BAILLIE GIFFORD & CO | 4.56% | 18.21M | $2.51B |
| 6 | State Street Corporation | 3.94% | 15.73M | $2.17B |
| 7 | Vanguard Portfolio Management LLC | 3.90% | 15.58M | $2.15B |
| 8 | Geode Capital Management, LLC | 2.43% | 9.71M | $1.34B |
| 9 | Morgan Stanley | 2.39% | 9.54M | $1.32B |
| 10 | Theleme Partners LLP | 2.02% | 8.06M | $1.11B |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MRNA
Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva
Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Vaccines Market Distribution by Type of Vaccine API, Targeted Patient Population, Type of Vaccines, Route of Administration, and Key Geographical Region - Trends and Forecasts Till 2035" has b…
How Is Moderna's Stock Performance Compared to Other Healthcare Stocks
Moderna has outpaced the healthcare sector, yet analysts remain skeptical about the stock’s outlook.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.
If You'd Invested in Moderna (MRNA) Stock 5 Years Ago, Here's How Much You'd Have Today (Hint: You'd Be Disappointed -- But Not If You Bought It 1 Year Ago.)
Moderna shares have soared, sunk, and soared again. You might want to consider them.
What Does Moderna (MRNA) Bird Flu Phase 3 Trial Mean For Its Growth?
Moderna (NasdaqGS:MRNA) has started a Phase 3 trial of its mRNA based bird flu vaccine, moving the program into late stage testing. The trial is supported by a major international partnership focused on pandemic preparedness. Moderna has ti…
Is Moderna (MRNA) Fully Valued After Its New 2032 Convertible Notes?
Moderna (MRNA) drew fresh attention after completing a US$2.6b zero coupon convertible notes offering due 2032 and separately announcing an additional US$2b 2032 convertible notes issue, both placed under Rule 144A. Moderna's recent complet…
MRNA — Frequently Asked Questions
What is the current share price of Moderna, Inc. (MRNA)?
As of 2026-09-07 16:24 PDT, Moderna, Inc. (MRNA) trades at $145.55 on NasdaqGS. Its 52-week range is $22.36 to $174.38.
What is the market capitalisation of MRNA?
Moderna, Inc. (MRNA) has a market capitalisation of $58.11B on NasdaqGS.
What is the P/E ratio of MRNA?
MRNA trades at a trailing price-to-earnings (P/E) ratio of -18.24. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 3.17.
What is the return on equity (ROE) of MRNA?
MRNA has a return on equity (ROE) of -39.00%. Its return on capital employed (ROCE) is -29.70%.
Is MRNA a good stock to buy?
This page provides a data-driven analysis of Moderna, Inc. (MRNA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.